<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(3)</volume><submitter>Li HM</submitter><pubmed_abstract>Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) have the potential to be a therapeutic option for myocardium restoration. However, hiPSC-CMs of varying maturation and transplantation routes exhibit different reactivity and therapeutic effects. We previously demonstrated that the saponin&lt;sup>+&lt;/sup> compound induces more mature hiPSC-CMs. The safety and efficacy of multi-route transplantation of saponin&lt;sup>+&lt;/sup> compound-induced hiPSC-CMs in a nonhuman primate with myocardial infarction will be investigated for the first time in this study. Our findings indicate that optimized hiPSC-CMs transplanted via intramyocardial and intravenous routes may affect myocardial functions by homing or mitochondrial transfer to the damaged myocardium to play a direct therapeutic role as well as indirect beneficial roles via anti-apoptotic and pro-angiogenesis mechanisms mediated by different paracrine growth factors. Due to significant mural thrombosis, higher mortality, and unilateral renal shrinkage, intracoronary transplantation of hiPSC-CMs requires closer attention to anticoagulation and caution in clinical use. Collectively, our data strongly indicated that intramyocardial transplantation of hiPSC-CMs is the ideal technique for clinical application; multiple cell transfers are recommended to achieve steady and protracted efficacy because intravenous transplantation's potency fluctuates. Thus, our study offers a rationale for choosing a therapeutic cell therapy and the best transplantation strategy for optimally induced hiPSC-CMs.</pubmed_abstract><journal>MedComm</journal><pagination>e289</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10248032</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Optimal transplantation strategy using human induced pluripotent stem cell-derived cardiomyocytes for acute myocardial infarction in nonhuman primates.</pubmed_title><pmcid>PMC10248032</pmcid><pubmed_authors>Feng YY</pubmed_authors><pubmed_authors>Xu AL</pubmed_authors><pubmed_authors>Li HM</pubmed_authors><pubmed_authors>Wang T</pubmed_authors><pubmed_authors>Cao YL</pubmed_authors><pubmed_authors>Sun K</pubmed_authors><pubmed_authors>Huang GR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Optimal transplantation strategy using human induced pluripotent stem cell-derived cardiomyocytes for acute myocardial infarction in nonhuman primates.</name><description>Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) have the potential to be a therapeutic option for myocardium restoration. However, hiPSC-CMs of varying maturation and transplantation routes exhibit different reactivity and therapeutic effects. We previously demonstrated that the saponin&lt;sup>+&lt;/sup> compound induces more mature hiPSC-CMs. The safety and efficacy of multi-route transplantation of saponin&lt;sup>+&lt;/sup> compound-induced hiPSC-CMs in a nonhuman primate with myocardial infarction will be investigated for the first time in this study. Our findings indicate that optimized hiPSC-CMs transplanted via intramyocardial and intravenous routes may affect myocardial functions by homing or mitochondrial transfer to the damaged myocardium to play a direct therapeutic role as well as indirect beneficial roles via anti-apoptotic and pro-angiogenesis mechanisms mediated by different paracrine growth factors. Due to significant mural thrombosis, higher mortality, and unilateral renal shrinkage, intracoronary transplantation of hiPSC-CMs requires closer attention to anticoagulation and caution in clinical use. Collectively, our data strongly indicated that intramyocardial transplantation of hiPSC-CMs is the ideal technique for clinical application; multiple cell transfers are recommended to achieve steady and protracted efficacy because intravenous transplantation's potency fluctuates. Thus, our study offers a rationale for choosing a therapeutic cell therapy and the best transplantation strategy for optimally induced hiPSC-CMs.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-27T02:22:49.648Z</modification><creation>2025-04-06T18:31:08.733Z</creation></dates><accession>S-EPMC10248032</accession><cross_references><pubmed>37303812</pubmed><doi>10.1002/mco2.289</doi></cross_references></HashMap>